Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004 Feb. 255(2):159-78. [Medline].
Cohen AS. Amyloidosis. N Engl J Med. 1967 Sep 7. 277(10):522-30 contd. [Medline].
Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007 Nov 27. 50(22):2101-10. [Medline].
Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: approaches to diagnosis and management. Cardiol Rev. 2010 Jan-Feb. 18(1):1-11. [Medline].
Sher T, Gertz MA. Recent advances in the diagnosis and management of cardiac amyloidosis. Future Cardiol. 2014 Jan. 10(1):131-46. [Medline].
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7. 349(6):583-96. [Medline].
Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997 Sep 25. 337(13):898-909. [Medline].
Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999 Mar. 84(3):218-21. [Medline].
Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol. 1983 Jul. 52(1):137-46. [Medline].
Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc. 1984 Aug. 59(8):547-55. [Medline].
Arbustini E, Merlini G, Gavazzi A, et al. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. Am Heart J. 1995 Sep. 130(3 pt 1):528-36. [Medline].
Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol. 1979 Sep. 44(3):413-7. [Medline].
Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med. 2000 Aug 15. 109(3):181-8. [Medline].
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005 Sep 27. 112(13):2047-60. [Medline].
Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007 Nov 20. 116(21):2420-6. [Medline].
Mohty D, Pradel S, Magne J, et al. Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Clin Res Cardiol. 2017 May. 106(5):331-40. [Medline].
Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977 May. 62(5):677-86. [Medline].
Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992 Apr 1. 79(7):1817-22. [Medline].
Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999 Dec. 13(6):1211-33, ix. [Medline].
Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998 Feb. 91(2):141-57. [Medline].
Usuku H, Obayashi K, Shono M, et al. Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy. Amyloid. 2013 Dec. 20(4):251-5. [Medline].
Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997 Feb 13. 336(7):466-73. [Medline].
Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018 Apr 1. 18(Suppl 2):s30-s35. [Medline]. [Full Text].
Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, et al. Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid. 2013 Dec. 20(4):263-8. [Medline].
Buck FS, Koss MN, Sherrod AE, Wu A, Takahashi M. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol. 1989 Jul. 2(4):372-7. [Medline].
Takashio S, Izumiya Y, Jinnin M, et al. Diagnostic and prognostic value of subcutaneous tissue biopsy in patients with cardiac amyloidosis. Am J Cardiol. 2012 Nov 15. 110(10):1507-11. [Medline].
Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20. 30(36):4541-9. [Medline].
Pennell DJ, Maceira AM. Magnetic resonance imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2009 Dec. 2(12):1378-80. [Medline].
Bodez D, Ternacle J, Guellich A, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016 Sep. 23(3):158-67. [Medline].
Ritts AJ, Cornell RF, Swiger K, Singh J, Goodman S, Lenihan DJ. Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration. Heart Fail Clin. 2017 Apr. 13(2):409-16. [Medline].
Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997 Nov 1. 80(9):1242-5. [Medline].
Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999 Dec 7. 131(11):838-41. [Medline].
Navarro JF, Rivera M, Ortuno J. Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol. 1992 Jul. 36(1):107-8. [Medline].
Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997 Dec 1. 80(11):1491-2. [Medline].
Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007 Sep 11. 69(11):1136-41. [Medline].
Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol. 1999 Apr. 40(4):507-35; quiz 536-8. [Medline].
Burroughs EI, Aronson AE, Duffy JR, Kyle RA. Speech disorders in systemic amyloidosis. Br J Disord Commun. 1991 Aug. 26(2):201-6. [Medline].
Bhogal S, Ladia V, Sitwala P, et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018 Jan. 43(1):10-34. [Medline].
Damy T, Deux JF, Moutereau S, et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid. 2013 Dec. 20(4):212-20. [Medline].
Aljama MA, Sidiqi MH, Dispenzieri A, et al. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Adv. 2019 Apr 23. 3(8):1226-9. [Medline]. [Full Text].
Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992 May. 13(5):623-7. [Medline].
Nishikawa H, Nishiyama S, Nishimura S, et al. Echocardiographic findings in nine patients with cardiac amyloidosis: their correlation with necropsy findings. J Cardiol. 1988 Mar. 18(1):121-33. [Medline].
Siqueira-Filho AG, Cunha CL, Tajik AJ, Seward JB, Schattenberg TT, Giuliani ER. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation. 1981 Jan. 63(1):188-96. [Medline].
Pradel S, Magne J, Jaccard A, et al. Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study. Int J Cardiovasc Imaging. 2019 May. 35(5):845-54. [Medline].
Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004 Feb 4. 43(3):410-5. [Medline].
Bellavia D, Abraham TP, Pellikka PA, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007 Oct. 20(10):1194-202. [Medline].
Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1990 Nov. 16(5):1135-41. [Medline].
Hongo M, Kono J, Yamada H, et al. Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease. J Cardiol. 1991. 21(2):391-401. [Medline].
Ha JW, Ommen SR, Tajik AJ, et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. Am J Cardiol. 2004 Aug 1. 94(3):316-9. [Medline].
Schiano-Lomoriello V, Galderisi M, Mele D, et al. Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography. 2016 Sep. 33(9):1335-43. [Medline].
Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 1. 18(9):1057-64. [Medline].
Bodez D, Ternacle J, Guellich A, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016 Sep. 23(3):158-67. [Medline].
Mohty D, Pibarot P, Dumesnil JG, et al. Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch Cardiovasc Dis. 2011 Dec. 104(12):611-8. [Medline].
Kwong RY, Heydari B, Abbasi S, et al. Characterization of cardiac amyloidosis by atrial late gadolinium enhancement using contrast-enhanced cardiac magnetic resonance imaging and correlation with left atrial conduit and contractile function. Am J Cardiol. 2015 Aug 15. 116(4):622-9. [Medline].
Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18. 111(2):186-93. [Medline].
Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009 Feb 15. 103(4):544-9. [Medline]. [Full Text].
Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009 Dec. 2(12):1369-77. [Medline].
Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008 Nov 25. 10:54. [Medline]. [Full Text].
Barison A, Aquaro GD, Pugliese NR, et al. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. J Intern Med. 2015 May. 277(5):605-14. [Medline].
Kuetting DL, Homsi R, Sprinkart AM, et al. Quantitative assessment of systolic and diastolic function in patients with LGE negative systemic amyloidosis using CMR. Int J Cardiol. 2017 Apr 1. 232:336-41. [Medline].
Falk RH, Lee VW, Rubinow A, Hood WB Jr, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol. 1983 Mar 1. 51(5):826-30. [Medline].
Cytawa W, Teodorczyk J, Lass P. Nuclear imaging of amyloidosis. Pol J Radiol. 2014 Jul 24. 79:222-7. [Medline]. [Full Text].
Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013 Mar 1. 6(2):195-201. [Medline]. [Full Text].
Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens. 2002 Nov. 11(6):649-55. [Medline].
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005 Feb 15. 95(4):535-7. [Medline].
Dubrey SW, Bilazarian S, LaValley M, Reisinger J, Skinner M, Falk RH. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997 Dec. 134(6):994-1001. [Medline].
Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J. 2002 Jan. 23(2):157-61. [Medline].
Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997 Oct. 30(4):1046-51. [Medline].
Pellikka PA, Holmes DR Jr, Edwards WD, Nishimura RA, Tajik AJ, Kyle RA. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med. 1988 Mar. 148(3):662-6. [Medline].
Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004 May. 147(5):919-23. [Medline].
Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian Blue stain for amyloid in cardiac pathology. J Clin Pathol. 1976 Jan. 29(1):22-6. [Medline]. [Full Text].
Kyle RA, Spencer RJ, Dahlin DC. Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Am J Med Sci. 1966 May. 251(5):501-6. [Medline].
Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?. Diagn Cytopathol. 2004 Mar. 30(3):178-81. [Medline].
US Food and Drug Administration. FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated. May 7, 2019; Accessed: May 8, 2019.
Maurer MS, Schwartz JH, Gundapaneni B, et al, for the ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018 Sep 13. 379(11):1007-16. [Medline]. [Full Text].
[Guideline] O'Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol. 2020 Feb. 36(2):159-69. [Medline]. [Full Text].
Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015 Jul 30. 126(5):612-5. [Medline].
Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol. 2016 Jun 28. 67(25):2941-8. [Medline].
Sanchorawala V, Wright DG, Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol. 2002 Jun. 117(4):886-9. [Medline].
Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004 Sep 15. 104(6):1888-93. [Medline].
Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001 Oct. 28(7):637-42. [Medline].
Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15. 103(8):2936-8. [Medline].
Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005 Apr 1. 105(7):2949-51. [Medline].
Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007 Jan 15. 109(2):457-64. [Medline].
Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol. 2008 Feb. 140(4):365-77. [Medline].
Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant. 2016 Jun 24. 6(2):380-8. [Medline].
Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981 Jun. 63(6):1285-8. [Medline].
Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009 May 12. 119(18):2490-7. [Medline].
Dubrey SW. Amyloid heart disease: a brief review of treatment options. Postgrad Med J. 2012 Dec. 88(1046):700-5. [Medline].
Migrino RQ, Truran S, Gutterman DD, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011 Dec. 301(6):H2305-12. [Medline].
Palladini G, Barassi A, Perlini S, et al. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid. 2011 Dec. 18(4):216-21. [Medline].
Ikeda S, Sekijima Y, Tojo K, Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid. 2011 Dec. 18(4):211-5. [Medline].
Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010 Dec 9. 116(24):5126-9. [Medline].
Tapan U, Seldin DC, Finn KT, et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood. 2010 Dec 2. 116(23):5071-2. [Medline].
McCausland KL, Quock TP, Rizio AA, et al. Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis. Br J Haematol. 2019 Jun. 185(5):998-1001. [Medline].
Manwani R, Hegenbart U, Mahmood S, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018 Nov 5. 8(11):101. [Medline]. [Full Text].
Kim HM, Sohn DW, Paeng JC. Prevalence of positive 99mTc-DPD scintigraphy as an indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly. Int Heart J. 2019 May 30. 60(3):643-7. [Medline].
